Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patients
2.2. Study Design and Treatment
2.3. Evaluations
2.4. Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Safety
3.3. DLT Cases
3.3.1. Case 1
3.3.2. Case 2
3.3.3. Case 3
3.4. Treatment Efficacy
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Curran, W.J., Jr.; Paulus, R.; Langer, C.J.; Komaki, R.; Lee, J.S.; Hauser, S.; Movsas, B.; Wasserman, T.; Rosenthal, S.A.; Gore, E.; et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: Randomized phase III trial RTOG 9410. J. Natl. Cancer Inst. 2011, 103, 1452–1460. [Google Scholar] [CrossRef] [PubMed]
- Yamamoto, N.; Nakagawa, K.; Nishimura, Y.; Tsujino, K.; Satouchi, M.; Kudo, S.; Hida, T.; Kawahara, M.; Takeda, K.; Katakami, N.; et al. Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J. Clin. Oncol. 2010, 28, 3739–3745. [Google Scholar] [CrossRef]
- Segawa, Y.; Kiura, K.; Takigawa, N.; Kamei, H.; Harita, S.; Hiraki, S.; Watanabe, Y.; Sugimoto, K.; Shibayama, T.; Yonei, T.; et al. Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J. Clin. Oncol. 2010, 28, 3299–3306. [Google Scholar] [CrossRef] [PubMed]
- Sause, W.T.; Scott, C.; Taylor, S.; Johnson, D.; Livingston, R.; Komaki, R.; Emami, B.; Curran, W.J.; Byhardt, R.W.; Turrisi, A.T. Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: Preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J. Natl. Cancer Inst. 1995, 87, 198–205. [Google Scholar] [CrossRef] [PubMed]
- Furuse, K.; Fukuoka, M.; Kawahara, M.; Nishikawa, H.; Takada, Y.; Kudoh, S.; Katagami, N.; Ariyoshi, Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 1999, 17, 2692–2699. [Google Scholar] [CrossRef]
- Ngwa, W.; Irabor, O.C.; Schoenfeld, J.D.; Hesser, J.; Demaria, S.; Formenti, S.C. Using immunotherapy to boost the abscopal effect. Nat. Rev. Cancer 2018, 18, 313–322. [Google Scholar] [CrossRef]
- Gandhi, L.; Rodríguez-Abreu, D.; Gadgeel, S.; Esteban, E.; Felip, E.; De Angelis, F.; Domine, M.; Clingan, P.; Hochmair, M.J.; Powell, S.F.; et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 2018, 378, 2078–2092. [Google Scholar] [CrossRef]
- Paz-Ares, L.; Luft, A.; Vicente, D.; Tafreshi, A.; Gümüş, M.; Mazières, J.; Hermes, B.; Çay Şenler, F.; Csőszi, T.; Fülöp, A.; et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 2018, 379, 2040–2051. [Google Scholar] [CrossRef]
- West, H.; McCleod, M.; Hussein, M.; Morabito, A.; Rittmeyer, A.; Conter, H.J.; Kopp, H.G.; Daniel, D.; McCune, S.; Mekhail, T.; et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019, 20, 924–937. [Google Scholar] [CrossRef]
- Borghaei, H.; Paz-Ares, L.; Horn, L.; Spigel, D.R.; Steins, M.; Ready, N.E.; Chow, L.Q.; Vokes, E.E.; Felip, E.; Holgado, E.; et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N. Engl. J. Med. 2015, 373, 1627–1639. [Google Scholar] [CrossRef]
- Theelen, W.S.M.E.; Chen, D.; Verma, V.; Hobbs, B.P.; Peulen, H.M.U.; Aerts, J.G.J.V.; Bahce, I.; Niemeijer, A.L.N.; Chang, J.Y.; de Groot, P.M.; et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: A pooled analysis of two randomised trials. Lancet Respir. Med. 2021, 9, 467–475. [Google Scholar] [CrossRef] [PubMed]
- Rahim, M.K.; Okholm, T.L.H.; Jones, K.B.; McCarthy, E.E.; Liu, C.C.; Yee, J.L.; Tamaki, S.J.; Marquez, D.M.; Tenvooren, I.; Wai, K.; et al. Dynamic CD8+ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes. Cell 2023, 186, 1127–1143. [Google Scholar] [CrossRef]
- Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Yokoi, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N. Engl. J. Med. 2017, 377, 1919–1929. [Google Scholar] [CrossRef]
- Spigel, D.R.; Faivre-Finn, C.; Gray, J.E.; Vicente, D.; Planchard, D.; Paz-Ares, L.; Vansteenkiste, J.F.; Garassino, M.C.; Hui, R.; Quantin, X.; et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J. Clin. Oncol. 2022, 40, 1301–1311. [Google Scholar] [CrossRef] [PubMed]
- Calvert, A.H.; Newell, D.R.; Gumbrell, L.A.; O’Reilly, S.; Burnell, M.; Boxall, F.E.; Siddik, Z.H.; Judson, I.R.; Gore, M.E.; Wiltshaw, E. Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 1989, 7, 1748–1756. [Google Scholar] [CrossRef]
- National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE), version 4.0; National Cancer Institute: Bethesda, MD, USA, 2009. [Google Scholar]
- Demaria, S.; Ng, B.; Devitt, M.L.; Babb, J.S.; Kawashima, N.; Liebes, L.; Formenti, S.C. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58, 862–870. [Google Scholar] [CrossRef]
- Liang, H.; Deng, L.; Chmura, S.; Burnette, B.; Liadis, N.; Darga, T.; Beckett, M.A.; Lingen, M.W.; Witt, M.; Weichselbaum, R.R.; et al. Radiation-induced equilibrium is a balance between tumor cell proliferation and T cell-mediated killing. J. Immunol. 2013, 190, 5874–5881. [Google Scholar] [CrossRef] [PubMed]
- Shaverdian, N.; Lisberg, A.E.; Bornazyan, K.; Veruttipong, D.; Goldman, J.W.; Formenti, S.C.; Garon, E.B.; Lee, P. LeePrevious radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: A secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol. 2017, 18, 895–903. [Google Scholar] [CrossRef]
- Antonia, S.J.; Villegas, A.; Daniel, D.; Vicente, D.; Murakami, S.; Hui, R.; Kurata, T.; Chiappori, A.; Lee, K.H.; de Wit, M.; et al. Overall Survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. 2018, 379, 2342–2350. [Google Scholar] [CrossRef]
- Deng, L.; Liang, H.; Burnette, B.; Beckett, M.; Darga, T.; Weichselbaum, R.R.; Fu, Y.X. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 2014, 124, 687–695. [Google Scholar] [CrossRef]
- Postow, M.A.; Callahan, M.K.; Barker, C.A.; Yamada, Y.; Yuan, J.; Kitano, S.; Mu, Z.; Rasalan, T.; Adamow, M.; Ritter, E.; et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N. Engl. J. Med. 2012, 366, 925–931. [Google Scholar] [CrossRef] [PubMed]
- Dovedi, S.J.; Adlard, A.L.; Lipowska-Bhalla, G.; McKenna, C.; Jones, S.; Cheadle, E.J.; Stratford, I.J.; Poon, E.; Morrow, M.; Stewart, R.; et al. Acquired resistance to fractionated radiotherapy can Be overcome by concurrent PD-L1 blockade. Cancer Res. 2014, 74, 5458–5468. [Google Scholar] [CrossRef] [PubMed]
- Palma, D.A.; Senan, S.; Tsujino, K.; Barriger, R.B.; Rengan, R.; Moreno, M.; Bradley, J.D.; Kim, T.H.; Ramella, S.; Marks, L.B.; et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis. Int. J. Radiat. Oncol. Biol. Phys. 2013, 85, 444–450. [Google Scholar] [CrossRef]
- Sekine, I.; Sumi, M.; Ito, Y.; Nokihara, H.; Yamamoto, N.; Kunitoh, H.; Ohe, Y.; Kodama, T.; Saijo, N.; Tamura, T. Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother. Oncol. 2006, 80, 93–97. [Google Scholar] [CrossRef]
- Shintani, T.; Kishi, N.; Matsuo, Y.; Ogura, M.; Mitsuyoshi, T.; Araki, N.; Fujii, K.; Okumura, S.; Nakamatsu, K.; Kishi, T.; et al. Incidence and risk factors of symptomatic radiation pneumonitis in non-small-cell lung cancer patients treated with concurrent chemoradiotherapy and consolidation durvalumab. Clin. Lung Cancer 2021, 22, 401–410. [Google Scholar] [CrossRef] [PubMed]
- Peters, S.; Felip, E.; Dafni, U.; Belka, C.; Guckenberger, M.; Irigoyen, A.; Nadal, E.; Becker, A.; Vees, H.; Pless, M.; et al. Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first-line chemoradiotherapy regimen in stage III non-small cell lung cancer—The ETOP Nicolas trial. Lung Cancer 2019, 133, 83–87. [Google Scholar] [CrossRef]
- Peters, S.; Felip, E.; Dafni, U.; Tufman, A.; Guckenberger, M.; Álvarez, R.; Nadal, E.; Becker, A.; Vees, H.; Pless, M.; et al. Progression-free and overall survival for concurrent nivolumab with standard concurrent chemoradiotherapy in locally advanced stage IIIA-B NSCLC: Results from the European thoracic oncology platform Nicolas Phase II trial (European thoracic oncology Platform 6–14). J. Thorac. Oncol. 2021, 16, 278–288. [Google Scholar] [CrossRef] [PubMed]
- Jabbour, S.K.; Berman, A.T.; Decker, R.H.; Lin, Y.; Feigenberg, S.J.; Gettinger, S.N.; Aggarwal, C.; Langer, C.J.; Simone, C.B.; Bradley, J.D.; et al. Phase 1 Trial of Pembrolizumab Administered Concurrently with Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial. JAMA Oncol. 2020, 6, 848–855. [Google Scholar] [CrossRef]
- Jabbour, S.K.; Lee, K.H.; Frost, N.; Breder, V.; Kowalski, D.M.; Pollock, T.; Levchenko, E.; Reguart, N.; Martinez-Marti, A.; Houghton, B.; et al. Pembroli-499 zumab Plus Concurrent Chemoradiation Therapy in Patients with Unresectable, Locally Advanced, Stage III Non-Small Cell 500 Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021, 7, 1–9. [Google Scholar] [CrossRef]
- Bradley, J.D.; Hu, C.; Komaki, R.R.; Masters, G.A.; Blumenschein, G.R.; Schild, S.E.; Bogart, J.A.; Forster, K.M.; Magliocco, A.M.; Kavadi, V.S.; et al. Long-term results of NRG oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer. J. Clin. Oncol. 2020, 38, 706–714. [Google Scholar] [CrossRef]
- Senan, S.; Brade, A.; Wang, L.H.; Vansteenkiste, J.; Dakhil, S.; Biesma, B.; Martinez Aguillo, M.; Aerts, J.; Govindan, R.; Rubio-Viqueira, B.; et al. PROCLAIM: Randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2016, 34, 953–962. [Google Scholar] [CrossRef] [PubMed]
No. of patients | 12 | |
Age: year | Median age | 65.5 |
range | 53–74 | |
Sex | Male/Female | 11/1 |
Performance Status | 0/1 | 11/1 |
Histology | Adeno/Squamous | 5/7 |
Stage | IIIA/IIIB/IIIC | 5/6/1 |
EGFR gene mutation | (+)/(−)/unknown | 1/1/10 |
Smoking history | current/ former/never | 3/9/0 |
Grade | ||||||
---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | All Grades | |
Leukopenia | 1 | 4 | 3 | 1 | 0 | 9 |
Neutropenia | 0 | 0 | 2 | 2 | 0 | 4 |
Lymphopenia | 0 | 1 | 1 | 0 | 0 | 2 |
Anemia | 3 | 4 | 0 | 0 | 0 | 7 |
Thrombocytopenia | 0 | 1 | 1 | 0 | 0 | 2 |
Radiation esophagitis | 3 | 3 | 0 | 0 | 0 | 6 |
Radiation pneumonitis | 3 | 3 | 0 | 0 | 0 | 6 |
Pneumonia | 0 | 1 | 2 | 0 | 0 | 3 |
Interstitial pneumonia | 0 | 0 | 2 | 0 | 1 | 3 |
Nausea | 7 | 1 | 0 | 0 | 0 | 8 |
Vomiting | 2 | 0 | 0 | 0 | 0 | 2 |
Constipation | 7 | 1 | 0 | 0 | 0 | 8 |
Diarrhea | 2 | 1 | 1 | 1 | 0 | 4 |
Fatigue | 6 | 2 | 0 | 0 | 0 | 8 |
Rash | 5 | 1 | 0 | 0 | 0 | 6 |
Decreased appetite | 3 | 2 | 1 | 0 | 0 | 6 |
Dysgeusia | 4 | 0 | 0 | 0 | 0 | 4 |
Insomnia | 4 | 0 | 0 | 0 | 0 | 4 |
Depilation | 2 | 1 | 0 | 0 | 0 | 3 |
Dizziness | 3 | 0 | 0 | 0 | 0 | 3 |
Objective Response | |
---|---|
CR | 0 (0) |
PR | 7 (58) |
SD | 2 (17) |
PD | 0 (0) |
NE | 3 (25) |
ORR | 7 (58) |
DCR | 9 (75) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Yamanaka, Y.; Ota, T.; Masuoka, Y.; Takeyasu, Y.; Nakamura, S.; Terashima, M.; Yoshioka, H.; Fukuoka, M.; Kurata, T. Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer. Cancers 2024, 16, 3127. https://doi.org/10.3390/cancers16183127
Yamanaka Y, Ota T, Masuoka Y, Takeyasu Y, Nakamura S, Terashima M, Yoshioka H, Fukuoka M, Kurata T. Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer. Cancers. 2024; 16(18):3127. https://doi.org/10.3390/cancers16183127
Chicago/Turabian StyleYamanaka, Yuta, Takayo Ota, Yutaka Masuoka, Yuki Takeyasu, Satoaki Nakamura, Masaaki Terashima, Hiroshige Yoshioka, Masahiro Fukuoka, and Takayasu Kurata. 2024. "Feasibility Study of Nivolumab in Combination with Carboplatin Plus Paclitaxel and Concurrent Thoracic Radiation in Patients with Untreated Unresectable Locally Advanced Non-Small Cell Lung Cancer" Cancers 16, no. 18: 3127. https://doi.org/10.3390/cancers16183127